Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24225996 | 0.96 | GLP1R (0.65) | GLP1RHDAC8HDAC3HDAC6HDAC1 | |
| SCHEMBL15359923 | 0.84 | GLP1R (0.69) | GLP1RNOD1 | |
| SCHEMBL15360200 | 0.84 | GLP1R (0.69) | GLP1RNOD1 | |
| SCHEMBL25898671 | 0.84 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL24227201 | 0.84 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL24311305 | 0.84 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL24311233 | 0.84 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL24311230 | 0.84 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL24311324 | 0.84 | GLP1R (0.83) | GLP1RNOD1 | |
| SCHEMBL14998210 | 0.84 | GLP1R (0.77) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025010-A1 | Modified GIP Peptide Analogues | ANTAG THERAPEUTICS APS (DK) | 2022-01-27 | — | — | US | disclosed |
| WO-2020115049-A1 | MODIFIED GIP PEPTIDE ANALOGUES | ANTAG THERAPEUTICS APS (DK) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025010-A1 | Modified GIP Peptide Analogues | GIPR, GLP1R, GPR119 | GLP1R 2/4885HDAC8 1587/4885HDAC3 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.